Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study

• DOI: 10.1371/journal.pone.0220163
• Publication Date: 2020-04-15T17:28:07Z
• Authors: Christian Christe...; Sandra Mjoll Jons...; Olafur Eysteinn S...
• Keywords: Blood product; Fetal bovine serum; Platelet Transfusion; Platelet lysate

Background Clinical application of mesenchymal stromal cells (MSCs) usually requires an in vitro expansion step to reach clinically relevant numbers. In cell necessitates supplementation basal mammalian culture medium with growth factors. To avoid using supplements containing animal substances, human platelet lysates (hPL) produced from expired and pathogen inactivated concentrates can be used place fetal bovine serum. However, globally, most transfusion units are currently not inactivated. As blood banks the sole source for hPL production, it is important ensure product safety standardized production methods. this proof-of-concept study we assessed feasibility producing inactivation applied after lysis by evaluating retention factors, cytokines, ability support MSC proliferation tri-lineage differentiation. Methodology/Principal findings Bone marrow-derived MSCs (BM-MSCs) were expanded differentiated derived (hPL-PIPL), amotosalen/ultraviolet A treatment platelets. Results compared those conventional (hPL-PIPC), donation. hPL-PIPL had lower concentrations soluble factors cytokines than hPL-PIPC treatment. When as culture, BM-MSCs proliferated at a reduced rate, but more consistently, hPL-PIPC. The differentiation was comparable between lysates. Conclusion/Significance These results suggest that functional untreated applying lysis. carried out post-expiration, may provide valuable solution further standardizing global methods, increasing pool starting material, meeting future demand animal-free culturing.